Table 3.
Meta-analysis of each secondary outcome
| Outcome | No. of studies | No. of patients | OR (95% CI) | P Value | I2% | Effects model |
|---|---|---|---|---|---|---|
| Clinical failure | 5 | 778 | 0.56 (0.37–0.85) | 0.12 | 44.9 | Fixed |
| Recurrence of bacteremia | 8 | 4017 | 1.12 (0.94–1.34) | 0.80 | 0 | Fixed |
| AEs | 5 | 672 | 0.37 (0.10–1.41) | 0 | 83.1 | Random |
| Hepatotoxicity | 4 | 645 | 0.12 (0.04–0.41) | 0.51 | 0 | Fixed |
| Nephrotoxicity | 3 | 484 | 0.36 (0.16–0.81) | 0.88 | 0 | Fixed |
| Anaphylaxis | 5 | 672 | 0.91 (0.36–2.99) | 0.53 | 0 | Fixed |
| Hematotoxicity | 4 | 511 | 0.56 (0.17–1.88) | 0.42 | 0 | Fixed |
| Discontinuation due to AEs | 3 | 468 | 0.24 (0.12–0.48) | 0.30 | 18 | Fixed |
AEs adverse effects, CI confidence interval, OR odds ratio